AI Engines For more Details: Perplexity Kagi Labs You
Osteoporosis: Clodronate is prescribed to treat osteoporosis, a condition characterized by decreased bone density and increased risk of fractures. Clodronate works by inhibiting bone resorption, the process by which bone tissue is broken down and reabsorbed by the body. By slowing down bone turnover, clodronate helps to increase bone density and reduce the risk of fractures in individuals with osteoporosis.
Paget's Disease of Bone: Clodronate is also used in the treatment of Paget's disease of bone, a chronic bone disorder characterized by abnormal bone remodeling. In Paget's disease, bone tissue is broken down and replaced at an accelerated rate, leading to weakened, enlarged, and deformed bones. Clodronate helps to regulate bone turnover by inhibiting osteoclast activity, the cells responsible for breaking down bone tissue. This helps to normalize bone turnover and improve bone structure and function in individuals with Paget's disease.
Hypercalcemia of Malignancy: Clodronate may be used off-label in the management of hypercalcemia of malignancy, a condition characterized by abnormally high levels of calcium in the blood due to cancer-related bone destruction. By inhibiting bone resorption, clodronate helps to reduce the release of calcium from the bones into the bloodstream, thereby lowering serum calcium levels and alleviating symptoms associated with hypercalcemia.
Bone Metastases: Clodronate has been investigated for its potential role in the prevention and treatment of bone metastases, particularly in patients with advanced cancer. Bone metastases occur when cancer cells spread from their original site to the bones, leading to bone destruction and increased risk of fractures and other complications. Clodronate may help to inhibit the growth and spread of cancer cells in the bones and reduce the risk of skeletal-related events, such as fractures and spinal cord compression, in patients with bone metastases.
Pain Relief: In addition to its effects on bone metabolism, clodronate may provide pain relief in individuals with bone disorders such as osteoporosis, Paget's disease, or bone metastases. By stabilizing bone structure and reducing bone turnover, clodronate can help alleviate bone pain and improve quality of life in affected individuals.
Side Effects: Common side effects of clodronate may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. Less common side effects may include headache, flu-like symptoms, fever, and musculoskeletal pain. Rare but serious side effects may include osteonecrosis of the jaw (ONJ), atypical femoral fractures, and allergic reactions. Patients should be monitored regularly for adverse effects during clodronate therapy, and treatment should be adjusted as needed based on individual response and tolerability.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 2.8 | 0.4 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.1 | 5 |
| Allergic Rhinitis (Hay Fever) | 0.4 | 1.7 | -3.25 |
| Allergies | 4.3 | 0.8 | 4.37 |
| Allergy to milk products | 0.5 | 0.5 | 0 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 1.5 | 3 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.2 | 8 |
| Ankylosing spondylitis | 2.2 | 0.4 | 4.5 |
| Anorexia Nervosa | 0.1 | 1.2 | -11 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.2 | 0.4 | 2 |
| Atherosclerosis | 0.7 | 1 | -0.43 |
| Atrial fibrillation | 2 | 0.7 | 1.86 |
| Autism | 4.6 | 4.6 | 0 |
| Barrett esophagus cancer | 0.4 | 0.1 | 3 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.3 | 1 | -2.33 |
| Brain Trauma | 0.7 | 0.4 | 0.75 |
| Carcinoma | 2.6 | 2 | 0.3 |
| Celiac Disease | 1.1 | 2.9 | -1.64 |
| Cerebral Palsy | 0.9 | 0.8 | 0.13 |
| Chronic Fatigue Syndrome | 2.9 | 3.5 | -0.21 |
| Chronic Kidney Disease | 1 | 0.9 | 0.11 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.5 | 0.6 |
| Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.8 | -1 |
| Colorectal Cancer | 1.7 | 0.7 | 1.43 |
| Constipation | 0.5 | 0.7 | -0.4 |
| Coronary artery disease | 0.4 | 0.8 | -1 |
| COVID-19 | 7.8 | 7.3 | 0.07 |
| Crohn's Disease | 3.6 | 3.2 | 0.13 |
| cystic fibrosis | 0.2 | 0.8 | -3 |
| deep vein thrombosis | 0.2 | 0.4 | -1 |
| Depression | 6.4 | 4 | 0.6 |
| Dermatomyositis | 0.1 | 0.3 | -2 |
| Eczema | 0.4 | 0.9 | -1.25 |
| Endometriosis | 1.6 | 0.9 | 0.78 |
| Eosinophilic Esophagitis | 0.4 | -0.4 | |
| Epilepsy | 1.7 | 1.1 | 0.55 |
| Fibromyalgia | 1.6 | 0.6 | 1.67 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 2.2 | 0.14 |
| gallstone disease (gsd) | 1.3 | 0.6 | 1.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.9 | -0.8 |
| Generalized anxiety disorder | 0.6 | 1.3 | -1.17 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 1 | 1.4 | -0.4 |
| Halitosis | 0.5 | 0.1 | 4 |
| Hashimoto's thyroiditis | 1.8 | 0.5 | 2.6 |
| Hidradenitis Suppurativa | 0.1 | 0.4 | -3 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.6 | 2.67 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 0.1 | 1 | -9 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.4 | 0.75 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 1.2 | 3.3 | -1.75 |
| Hypothyroidism | 1.1 | -1.1 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 1.5 | -1.5 | |
| Inflammatory Bowel Disease | 2.2 | 3.2 | -0.45 |
| Insomnia | 0.7 | 0.7 | 0 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.6 | 0.4 | 0.5 |
| Irritable Bowel Syndrome | 2.3 | 1.9 | 0.21 |
| Liver Cirrhosis | 2.5 | 1.7 | 0.47 |
| Long COVID | 3.9 | 6.1 | -0.56 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.8 | 0.7 | 0.14 |
| ME/CFS with IBS | 0.2 | 1.9 | -8.5 |
| ME/CFS without IBS | 1.5 | 1.5 | 0 |
| Menopause | 1.8 | 1.8 | |
| Metabolic Syndrome | 4.8 | 4.4 | 0.09 |
| Mood Disorders | 7.7 | 4.4 | 0.75 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.4 | 0.5 |
| Multiple Sclerosis | 3.4 | 1.7 | 1 |
| Multiple system atrophy (MSA) | 0.8 | 0.7 | 0.14 |
| Neuropathy (all types) | 0.5 | 0.1 | 4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 3.7 | -1.64 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 5.9 | 2.2 | 1.68 |
| obsessive-compulsive disorder | 3.3 | 1.9 | 0.74 |
| Osteoarthritis | 0.8 | 0.8 | |
| Osteoporosis | 1.1 | 0.6 | 0.83 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 1.4 | 1.6 | -0.14 |
| Polycystic ovary syndrome | 0.8 | 1.1 | -0.38 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.3 | -2 |
| Premenstrual dysphoric disorder | 1.1 | 0.1 | 10 |
| primary biliary cholangitis | 0.3 | 0.4 | -0.33 |
| Psoriasis | 3.1 | 0.5 | 5.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.6 | 2.5 | 0.44 |
| Rosacea | 0.7 | 0.4 | 0.75 |
| Schizophrenia | 4.4 | 1.1 | 3 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 2 | 2 | 0 |
| Sleep Apnea | 0.7 | 1.2 | -0.71 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.7 | -1.33 |
| Stress / posttraumatic stress disorder | 1.4 | 1.9 | -0.36 |
| Systemic Lupus Erythematosus | 2 | 1.6 | 0.25 |
| Tic Disorder | 0.3 | 1.1 | -2.67 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 1.6 | 1.5 | 0.07 |
| Type 2 Diabetes | 4.7 | 2.4 | 0.96 |
| Ulcerative colitis | 1.8 | 1.7 | 0.06 |
| Unhealthy Ageing | 2.3 | 0.9 | 1.56 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.